They show how changes in genetic material affect the protein profile of the tumor cells, and thus the mechanisms involved in the disease. Multiple myeloma is a form of cancer in which the immune ...

Tumor suppressor genes: Another genetic mutation that can lead to multiple myeloma is a change to tumor suppressor genes. These genes slow cell growth or trigger cell death at appropriate times.

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

A single tumor is referred to as a "solitary plasmacytoma" and these can occur alone or as part of systemic multiple myeloma. In the U.S., the average lifetime risk of multiple myeloma is less ...

Novel therapies are unmet needs in multiple myeloma (MM). Monoclonal antibody ... and specifically deliver cytotoxic drugs to the tumor. A variety of highly cytotoxic compounds are being evaluated ...

During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic malignancies. The overall prognosis is driven by tumor biology but other factors such ...

which is highly expressed in multiple myeloma cells. Daratumumab works by activating the immune system to target and destroy cancer cells, leading to rapid tumor cell death through various immune ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...